A predictable pattern emerges for many people on semaglutide: strong initial weight loss in the first three to six months, then a gradual slowdown, then a plateau where the scale doesn’t move for weeks or months. Some people interpret this as the medication failing. The reality is more nuanced.
Why the plateau happens
Semaglutide works primarily through appetite suppression. It slows gastric emptying, signals satiety to the brain, and reduces food cravings. At maximum dose, it doesn’t eliminate hunger — it modulates it.
As the body loses weight, it adapts. A smaller body burns fewer calories. The same absolute calorie deficit that produced rapid weight loss early in treatment produces a smaller and smaller deficit as body weight falls. Eventually, the new calorie intake (reduced by appetite suppression) and the new calorie expenditure (reduced by lower body weight and metabolic adaptation) reach equilibrium — and weight stabilizes.
The STEP trials that established semaglutide’s efficacy found that weight loss in most participants plateaued at around 60 weeks. The average total weight loss was 14.9% of body weight at that point. The plateau at 60 weeks wasn’t a sign the drug stopped working — it was the expected outcome as the system reached a new equilibrium.
What to assess at plateau
Before concluding that the medication is no longer effective, a few things are worth evaluating.
Dose. Semaglutide is typically started at 0.25 mg weekly and titrated up to 2.4 mg weekly over several months. If you’re on a lower dose than the maximum, dose escalation may restart weight loss. Many plateaus reflect under-dosing rather than pharmacological resistance.
Protein intake. Adequate protein (1.0–1.5 g/kg body weight) is important both for maintaining muscle during weight loss and for satiety. Insufficient protein can allow appetite to creep back as the medication’s suppression effect is overridden by hunger hormones.
Physical activity. Semaglutide alone produces greater weight loss than the combination of semaglutide plus placebo-level physical activity in trials. Adding or increasing resistance training can restart weight loss by increasing muscle mass and metabolic rate.
The option of dose escalation
For patients who have reached maximum approved semaglutide dose and plateaued, switching to tirzepatide is an option some prescribers are exploring. The dual mechanism of tirzepatide (GLP-1 and GIP agonism) has shown greater average weight loss in clinical trials, and preliminary real-world data suggests that some people who plateau on semaglutide see resumed weight loss after switching.
This is an area of ongoing research rather than established protocol. The right answer depends on individual circumstances, insurance coverage, and prescriber judgment.
Maintenance as a valid goal
It’s also worth reframing the plateau. If semaglutide helped produce meaningful weight loss that is now being maintained — even without further loss — that is a clinical success. The trials show that people who stop taking GLP-1 medications regain most of the lost weight. Maintenance at a lower weight, sustained by ongoing medication, is a legitimate and meaningful outcome.
The question isn’t just “am I still losing?” It’s “has my metabolic health improved, and is it being maintained?” Blood sugar, blood pressure, and other markers may continue improving even after scale weight stabilizes.
This content is for educational purposes only and is not medical advice. Consult your healthcare provider before making changes to your diet, supplements, or medications.
